Validation of tobramycin monitoring in adolescent and adult patients with cystic fibrosis.
The predictive performance of a dosage calculation method for the optimization of tobramycin therapy was studied retrospectively in 29 patients with cystic fibrosis. The dosage calculation method was based on a linear one-compartment open model. It used peak and trough serum concentrations of the aminoglycoside. Bias in the peak concentration was 0.20 mg/L and precision was 1.2 mg/L. Bias in the trough concentration was -0.06 mg/L and precision was 0.33 mg/L. The results were clinically satisfactory. Comparison with previously published results of the predictive performance of other dosage calculation methods showed that the method studied was at least as good.
Touw
D J
DJ
The Hague Hospitals Central Pharmacy, The Netherlands.
Vinks
A A
AA
Heijerman
H G
HG
Bakker
W
W
D000293:Adolescent; D000328:Adult; D000375:Aging / Q000097:blood; D003550:Cystic Fibrosis / Q000097:blood / Q000188:drug therapy*; D004334:Drug Administration Schedule; D016503:Drug Delivery Systems; D016903:Drug Monitoring / Q000379:methods; D005260:Female; D006801:Humans; D008297:Male; D008954:Models, Biological; D011237:Predictive Value of Tests; D015203:Reproducibility of Results; D012189:Retrospective Studies; D014031:Tobramycin / Q000008:administration & dosage* / Q000097:blood*
D014031:Tobramycin